| 2024-04-18 | -0.11 % |
|
| 2024-04-16 | -0.9 % |
|
| 2024-04-09 | +0.12 % |
|
| 2024-04-08 | -1.12 % |
|
| 2024-04-05 | +0.26 % |
|
| 2024-04-04 | -1.72 % |
|
| 2024-04-03 | -0.35 % |
|
| 2024-04-02 | -0.49 % |
- The article discusses a Biologics License Application (BLA) by AstraZeneca and Daiichi Sankyo for datopotamab deruxtecan (Dato-DXd) for the treatment of breast cancer, which has been accepted in the US, potentially providing an alternative to conventional chemotherapy for patients. Merck & Co. (MRK) stock went down last night, likely in reaction to various factors affecting the pharmaceutical industry, market conditions, or specific company developments.
- Summary: The article discusses the acceptance of the Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) by the U.S. for the treatment of advanced breast cancer, along with the stock market reaction, leading to a slight decline in Merck & Co. (MRK) stock.
Reason for MRK stock decline: The slight decline in Merck & Co. (MRK) stock may be attributed to various factors such as market sentiment, overall economic conditions, investor reactions to specific news or events, or profit-taking by investors.
- The article discusses a clinical trial collaboration between BioInvent and Merck & Co., Inc. for a study involving monoclonal antibody BI-1910 in combination with KEYTRUDA. Merck & Co.(MRK) stock went down last night by -0.49%, which could be due to various factors such as market sentiment, overall industry performance, economic conditions, or specific news related to the company.
|
| 2024-04-01 | -0.73 % |
|
| 2024-03-28 | +0.15 % |
- The article discusses how institutional investors have adjusted their positions in Merck & Co., Inc. (MRK) stock, resulting in a slight increase in the stock price, with S.A. Mason LLC decreasing its stake, while other hedge funds have increased their positions, leading to a positive market response due to increased interest and confidence in the company's performance and potential growth.
- Summary: Blackston Financial Advisory Group LLC acquired a new stake in Merck & Co., Inc. (MRK) stock, which resulted in a 0.15% increase in MRK stock value; this increase may be attributed to the continued interest of various institutional investors and hedge funds in adding to their stakes in MRK.
Reason for MRK stock increase: The rise in MRK stock value can be attributed to the acquisition of a new stake in the company by Blackston Financial Advisory Group LLC and continued interest from various institutional investors and hedge funds in adding to their stakes in MRK, as indicated by recent filings and transactions disclosed with the Securities and Exchange Commission.
- The article discusses how RNC Capital Management LLC reduced its shares in Merck & Co., Inc. (MRK) by 21.1% in the fourth quarter, with various other institutional investors also making changes to their positions in the company. The increase in Merck & Co. stock price could be due to positive analyst ratings and the company's recent strong financial performance and dividend announcements.
|
| 2024-03-27 | +4.96 % |
|
| 2024-03-26 | +0.17 % |
- Alaska Wealth Advisors reduced its holding in Merck & Co., Inc. (NYSE:MRK) shares by 5.4% in the fourth quarter, leading to a 0.17% increase in the stock price, possibly due to other institutional investors adjusting their positions positively and strong financial performance from the company, including beating analysts' earnings estimates.
- The article discusses the increase in Merck & Co. (MRK) stock by 0.17% and mentions that Kingswood Wealth Advisors LLC raised its position in the company, alongside other hedge funds making changes to their positions. The increase in stock value can be attributed to these investments and acquisitions, indicating a positive outlook on the company by institutional investors.
- The article discusses how Windward Capital Management Co. CA increased its stake in Merck & Co., Inc. (MRK) and several other institutional investors made changes to their positions, which led to a 0.17% increase in MRK stock price, with the stock likely experiencing an upward trend due to increased institutional investment and positive analyst ratings, alongside strong earnings performance and dividends at Merck & Co., Inc.
|
| 2024-03-25 | +1.18 % |
- The article discusses Aerovate Therapeutics, Inc.'s financial results and recent business highlights, particularly focusing on the AV-101 trial for patients with pulmonary arterial hypertension (PAH). The stock price of Merck & Co.(MRK) likely went up due to the positive developments and milestones achieved by Aerovate Therapeutics, Inc., which has the potential to impact the treatment landscape for PAH patients positively.
- The article discusses Merck & Co., Inc. (MRK) stock, which was up 1.18%. The stock rose following positive recommendations and upgraded ratings from several equities research analysts, including increased price targets and buy ratings, indicating favorable market sentiment towards the company based on its financial performance, earnings reports, dividends, and analyst predictions.
|
| 2024-03-21 | -0.19 % |
|
| 2024-03-20 | +1.35 % |
|
| 2024-03-19 | +0.63 % |
- The article discusses how Sugarloaf Wealth Management LLC increased its holdings in Merck & Co., Inc. (NYSE: MRK) by 2.5% during the 4th quarter, with various other hedge funds also buying shares, resulting in a 0.63% increase in the stock, mainly due to institutional investors' interest in the company and positive analyst ratings predicting growth and ongoing financial performance.
- Summary: Foundation Resource Management Inc. reduced its stake in Merck & Co., Inc. (MRK) by 1.6% in the 4th quarter, and several other large investors made changes to their positions in MRK, ultimately resulting in MRK stock going up by 0.63%. MRK's last posted profits beat analysts' estimates and it has received positive ratings and price targets from various research reports.
Reason MRK stock went up: The increase in MRK stock can be attributed to institutional investors like Foundation Resource Management Inc. and others increasing their stake in the company, positive quarterly earnings results, positive analyst ratings, and the upcoming dividend payment, showcasing strong investor confidence in the company's future growth potential.
- The article discusses NGM Biopharmaceuticals presenting clinical data at the American Association for Cancer Research, and Merck & Co.'s drug Keytruda being part of the study that boosting Merck & Co. stock.
|
| 2024-03-18 | -0.07 % |
|
| 2024-03-15 | +0.84 % |
- The article discusses Merck & Co. (MRK) stock, which was up by 0.84% last night, and the reason for the increase is the strategic collaboration between MSD Animal Health, a division of Merck & Co., and FarmSee, a company providing AI solutions for swine monitoring, which has received investment and will integrate its technology into MSD Animal Health's offerings for swine producers.
- Merck & Co., Inc. (MRK) stock went up by 0.84% following the positive results from its Phase 3 KEYNOTE-A18 trial, which showed a significant improvement in overall survival for patients with high-risk locally advanced cervical cancer when treated with KEYTRUDA in combination with chemoradiotherapy. The stock rise is likely attributed to the promising trial outcomes, the company's focus on innovation and expanding KEYTRUDA's applications, its strong financial performance metrics, including a track record of consistent dividend payments, and investor confidence in the company's future growth potential and drug portfolio.
- The article discusses Merck & Co. (MRK) announcing positive results from the Phase 3 KEYNOTE-A18 trial, showing a statistically significant improvement in overall survival (OS) for newly diagnosed patients with high-risk locally advanced cervical cancer when treated with KEYTRUDA in combination with chemoradiotherapy, which led to the stock going up by 0.84% last night. The stock likely went up due to the promising trial results indicating the potential for KEYTRUDA as an effective treatment option for cervical cancer, which could lead to increased sales and positive investor sentiment.
|
| 2024-03-13 | -0.41 % |
|
| 2024-03-12 | -0.09 % |
- The article discusses IDEAYA Biosciences' clinical collaboration with Merck to evaluate IDE161 in combination with KEYTRUDA in patients with endometrial cancer, and the potential benefits of this combination therapy. Merck & Co.(MRK) stock went down by -0.09% due to factors such as market conditions, investor sentiment, company performance, and industry news.
- The article discusses Merck & Co., Inc. (MRK) announcing a quarterly dividend and its financial performance, including an increase in its dividend payout over the last few years. The stock went down by 0.09%, and this drop could be attributed to various factors, such as market conditions, investor sentiment, or profit-taking by stakeholders following an increase in the stock price.
|
| 2024-03-11 | -0.59 % |
- The article discusses Merck & Co Inc MRK posting a new trial for Moderna Inc’s MRNA V940 on clinicaltrials.gov, which caused a -0.59% decline in MRK stock, attributed to investors reacting to this particular trial outcome.
- NGM Biopharmaceuticals, Inc. provided recent business highlights including progress in patient enrollment for drug trials, discussions with regulators, financial results, and upcoming initiatives, with a focus on completing patient enrollment for NGM707 and potential trials for NGM120 and aldafermin, leading to a -0.59% drop in Merck & Co. (MRK) stock due to various factors affecting the company and industry.
- The article discusses Merck & Co.'s acquisition of Harpoon Therapeutics, Inc. and the completion of the transaction, which led to a -0.59% decrease in Merck's stock value. The stock could have gone down due to market reactions to the deal, factors affecting the pharmaceutical industry, general economic conditions, or investor sentiment.
|
| 2024-03-08 | -0.4 % |
- Merck & Co. Inc. (MRK) reported a mixed performance in its fourth-quarter earnings call for 2023, with a decline in net sales and earnings per share, despite a resilient healthcare sector; the stock was down by -0.4%, and this may be attributed to the company's challenging year and the headwinds it faces, despite its commitment to sustainability, strategic acquisitions, and growth strategies in various sectors.
- The article discusses the rise in the biotech industry due to recent developments and optimism, as well as an increase in M&A activity. Merck & Co. (MRK) stock went down by -0.4% last night, and possible reasons for this decline could be related to factors affecting the overall market sentiment, such as specific company performance, industry trends, or broader economic conditions.
|
| 2024-03-07 | +0.19 % |
|
| 2024-03-06 | +0.75 % |
- Summary: iTeos Therapeutics, Inc. appointed Jill DeSimone to its Board of Directors, who has a background in life sciences and was previously the President of U.S. Oncology at Merck & Co., Inc., contributing to Merck's oncology division's substantial growth.
Reason for Merck & Co.(MRK) stock going up: Merck & Co.(MRK) stock may have gone up due to positive sentiment surrounding the company after news of Jill DeSimone's appointment to iTeos Therapeutics, Inc.'s Board of Directors, given her successful track record at Merck & Co., Inc.
- The article provides information about the appointment of Jill DeSimone to the Board of Directors of iTeos Therapeutics, Inc., a clinical-stage biopharmaceutical company, leading to a 0.75% increase in Merck & Co. (MRK) stock due to DeSimone's extensive experience and successful track record as President of U.S. Oncology at Merck & Co., Inc., and her potential value in contributing insights for iTeos' development of immuno-oncology therapeutics.
- The article discusses Gilead Sciences, Inc. and Merck's Phase 2 clinical study on the combination treatment of islatravir and lenacapavir for individuals with HIV, which showed positive results, maintaining a high rate of viral suppression, leading to a 0.75% increase in Merck & Co. (MRK) stock. The stock likely went up due to the promising data on the investigational once-weekly oral combination regimen, offering potential benefits in terms of adherence and addressing challenges faced by some individuals on daily oral therapies.
|
| 2024-03-05 | -0.98 % |
- The article highlights Merck & Co.'s participation in an upcoming fireside chat at the Barclays Global Healthcare Conference, emphasizing the company's commitment to research and innovative health solutions, while also mentioning the inherent risks and uncertainties in the pharmaceutical industry and potential factors impacting the company's stock performance. Merck & Co.'s stock went down by 0.98% last night, possibly influenced by general economic factors, industry conditions, regulatory challenges, and other risks indicated in the forward-looking statement of the company.
- The article discusses the growth of the pancreatic cancer treatment market due to an increasing incidence of pancreatic cancer, particularly in the geriatric population, driving the demand for related drugs, leading to a projected market size growth to USD 6.85 billion by 2029. The market is also seeing increased focus on R&D and regulatory approval for new treatments. Merck & Co.(MRK) stock may have gone down due to factors like new drug development and clinical trials by competitors like Oncolytics Biotech® Inc., increased market competition, and shifting focuses in the biotech and pharma industries.
- Summary: LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, achieved a clinical development milestone with Pfizer for PF-08046052, receiving a payment of $7 million, impacting Merck & Co. (MRK) stock which dropped by -0.98% overnight.
Reason for Merck & Co. (MRK) stock decline: The drop in Merck & Co. (MRK) stock may be attributed to news related to LAVA Therapeutics N.V. achieving a clinical development milestone with Pfizer for PF-08046052, introducing potential competition or strategic developments impacting investor sentiment towards Merck & Co.
|
| 2024-03-04 | -2.29 % |
|
| 2024-02-29 | -0.81 % |
- The article discusses Merck & Co., Inc. (MRK) stock, which was down by -0.81% last night, and provides information on analysts' ratings, price objectives, recent insider trading, institutional investments, and financial performance of the company. The stock price may have gone down due to various factors, such as profit-taking after recent gains, market conditions, or changes in analyst recommendations.
|
| 2024-02-27 | +0.15 % |
- The article discusses an adjustment to the price target for C4 Therapeutics, mentioning the company's improved cash position, cost reduction measures, and progress in its clinical programs, which led to UBS maintaining a Buy rating on the stock with expectations for positive data updates in the latter half of 2024, potentially boosting commercial prospects.
- The article discusses Ligand Pharmaceuticals Incorporated's financial results and operating forecast, with key highlights being a transformative year in 2023 and expectations for continued momentum in 2024. Merck & Co. (MRK) stock increased by 0.15% due to the announcement that the FDA accepted for priority review a new BLA for V116, an investigational pneumococcal vaccine.
- Merck & Co. (MRK) stock went up by 0.15% after the company's president, Joseph Romanelli, participated in a fireside chat at the TD Cowen 44th Annual Health Care Conference, where they discussed the company's purpose of using leading-edge science to save and improve lives through the development of medicines and vaccines.
|
| 2024-02-26 | -0.47 % |
|
| 2024-02-23 | +0.15 % |
|
| 2024-02-22 | +0.89 % |
|
| 2024-02-20 | -0.33 % |
|
| 2024-02-16 | +0.99 % |
|
| 2024-02-15 | +0.57 % |
|
| 2024-02-14 | +0.31 % |
|
| 2024-02-09 | -0.92 % |
|
| 2024-02-08 | -0.67 % |
|
| 2024-02-07 | +0.47 % |
|
| 2024-02-06 | +0.55 % |
|
| 2024-02-05 | -0.18 % |
|
| 2024-02-01 | +4.64 % |
|
| 2024-01-31 | -0.72 % |
|
| 2024-01-30 | +0.31 % |
|
| 2024-01-29 | +0.38 % |
|
| 2024-01-26 | +0.57 % |
|
| 2024-01-25 | +1.05 % |
|
| 2024-01-23 | +0.34 % |
|
| 2024-01-22 | +0.45 % |
|
| 2024-01-19 | +0.3 % |
|
| 2024-01-17 | -0.3 % |
|
| 2024-01-16 | -0.12 % |
|
| 2024-01-12 | +0.17 % |
|
| 2024-01-09 | +0.89 % |
|
| 2024-01-08 | +0.14 % |
|
| 2024-01-05 | +0.18 % |
|
| 2024-01-03 | +1.35 % |
|
| 2024-01-02 | +3.87 % |
|
| 2023-12-29 | +0.23 % |
|
| 2023-12-28 | +0.73 % |
|
| 2023-12-27 | +0.33 % |
|
| 2023-12-22 | +1.23 % |
|
| 2023-12-21 | +0.98 % |
|
| 2023-12-20 | -1.06 % |
|
| 2023-12-19 | +0.42 % |
|
| 2023-12-18 | +0.88 % |
|
| 2023-12-15 | -0.73 % |
|
| 2023-12-14 | -1.15 % |
|
| 2023-12-12 | -0.01 % |
|
| 2023-12-11 | +0.6 % |
|
| 2023-12-08 | -0.13 % |
|
| 2023-12-07 | -1.66 % |
|
| 2023-12-06 | -0.56 % |
|
| 2023-12-05 | +1.11 % |
|
| 2023-12-04 | +1.55 % |
|
| 2023-11-30 | +1.33 % |
|
| 2023-11-29 | +0.95 % |
|
| 2023-11-28 | -1.23 % |
|
| 2023-11-24 | +0.19 % |
|
| 2023-11-22 | -0.52 % |
|
| 2023-11-21 | -0.46 % |
|
| 2023-11-20 | +0.91 % |
|
| 2023-11-17 | -0.24 % |
|
| 2023-11-15 | -0.8 % |
|
| 2023-11-14 | -0.29 % |
|
| 2023-11-13 | +1.07 % |
|
| 2023-11-10 | -0.97 % |
|
| 2023-11-08 | +0.38 % |
|
| 2023-11-07 | -0.33 % |
|
| 2023-11-06 | +0.93 % |
|
| 2023-11-03 | +0.52 % |
|
| 2023-11-02 | |
- Moderna Inc. reported a wider loss than expected in the third quarter and lowered its full-year sales outlook, leading to a 4.8% decline in its stock price; the loss was driven by non-cash charges related to resizing and tax valuation allowances, including write-downs on excess and obsolete COVID products.
- Merck & Co. (MRK) stock went down by 0.0% last night, and the reason for the decrease is not provided in the article.
- Merck & Co. (MRK) stock went down by 0.0% last night, likely due to the company's financial results for the third quarter of 2023, which showed a decrease in revenue and net income compared to the same period in 2022. Factors contributing to the decline include decreased sales in the Women's Health segment due to generic competition for NuvaRing, as well as unfavorable discount rates and a change in the go-to-market model for Nexplanon. The Biosimilars segment saw growth, driven by strong demand for Renflexis and Ontruzant. The Established Brands segment also experienced growth, despite the impact of Volume Based Procurement initiatives in China. The company has updated its full year 2023 financial guidance, narrowing and lowering the revenue range and adjusting the EBITDA margin range to reflect current foreign currency exchange rates, changes to the go-to-market model for Nexplanon, and macroeconomic factors in China.
|
| 2023-11-01 | +0.15 % |
|
| 2023-10-31 | +0.02 % |
|
| 2023-10-27 | -2.59 % |
|
| 2023-10-26 | +1.85 % |
|
| 2023-10-23 | +0.66 % |
|
| 2023-10-20 | +2.23 % |
|
| 2023-10-19 | -1.53 % |
|
